You are here: Industry Insights > Myelofibrosis

News List

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model prnasia
August 05, 2021
Clinical stage drug development company Pharmaxis Ltd today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) ...
CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis drugs
June 21, 2021
CTI BioPharma Corp.today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L)
FDA Approves Inrebic Capsules for Myelofibrosis drugs
August 19, 2019
Inrebic (fedratinib) capsules have been approved to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis, making it the second drug approved to treat patients with this disease...
FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis drugs
August 19, 2019
Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or ...
CTI BioPharma to Move to Phase 3 Study of Pacritinib for Myelofibrosis americanpharmaceuticalreview
July 19, 2019
CTI BioPharma announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration (FDA) for the continued development of its investigational myelofibrosis treatment candidate, pacritinib. Following this meeting ...